Amarin reported $-2.26M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 392M Sep/2026